HER1/EGFR inhibitor-associated rash

Future directions for management and investigation outcomes from the HER1/EGFR inhibitor rash management forum

Román Pérez-Soler, Jean Pierre Delord, Allan Halpern, Karen Kelly, James Krueger, Bartomeu Massuti Sureda, Joachim Von Pawel, Jennifer Temel, Salvatore Siena, Denis Soulières, Leonard Saltz, James Leyden

Research output: Contribution to journalArticle

226 Citations (Scopus)

Abstract

Skin rash associated with HER1/epidermal growth factor receptor (EGFR) inhibitors is common. The lack of clinical and patient guidance for this often chronic and sometimes distressing side effect makes rash management and etiology investigation high priorities. To address this, oncologists and dermatologists with experience with HER1/EGFR inhibitors attended the HER1/EGFR Inhibitor Rash Management Forum. Recommendations include continued analysis of the correlation between rash and clinical outcome and improving the accuracy and reproducibility of terminology and grading systems. Because acne vulgaris has a unique pathology, and the pathology and etiology of rash are unclear yet distinct from acne vulgaris, using such terms as acne, acne-like, or acneiform should be avoided. Until there is a specific dermatological definition, rash is best described using phenotypic terms for its appearance and location. It is currently unknown which agents are best for treating rash. Clinical trials of rash treatments are urgently required, and suggestions for agents to consider are made based on current knowledge. The effect of dose reduction or interruption on rash should also be investigated. Secondarily infected rash may be more frequent than has been previously recognized, and some investigators favor empiric use of an oral antibiotic if this appears to be the case. Suggestions for patients include makeup to camouflage the rash and an emollient to prevent and alleviate skin dryness. The increasing use of HER1/EGFR-targeted agents makes managing rash important. We hope the outcomes from this Forum provide background for future studies.

Original languageEnglish (US)
Pages (from-to)345-356
Number of pages12
JournalOncologist
Volume10
Issue number5
DOIs
StatePublished - May 2005
Externally publishedYes

Fingerprint

Exanthema
Epidermal Growth Factor Receptor
Acne Vulgaris
Direction compound
Emollients
Pathology
Terminology
Research Personnel
Clinical Trials
Anti-Bacterial Agents
Skin

Keywords

  • Adverse event
  • HER1/EGFR
  • Monoclonal antibody
  • NSCLC
  • Rash
  • Survival
  • Tyrosine kinase inhibitor

ASJC Scopus subject areas

  • Cancer Research
  • Hematology

Cite this

HER1/EGFR inhibitor-associated rash : Future directions for management and investigation outcomes from the HER1/EGFR inhibitor rash management forum. / Pérez-Soler, Román; Delord, Jean Pierre; Halpern, Allan; Kelly, Karen; Krueger, James; Sureda, Bartomeu Massuti; Von Pawel, Joachim; Temel, Jennifer; Siena, Salvatore; Soulières, Denis; Saltz, Leonard; Leyden, James.

In: Oncologist, Vol. 10, No. 5, 05.2005, p. 345-356.

Research output: Contribution to journalArticle

Pérez-Soler, R, Delord, JP, Halpern, A, Kelly, K, Krueger, J, Sureda, BM, Von Pawel, J, Temel, J, Siena, S, Soulières, D, Saltz, L & Leyden, J 2005, 'HER1/EGFR inhibitor-associated rash: Future directions for management and investigation outcomes from the HER1/EGFR inhibitor rash management forum', Oncologist, vol. 10, no. 5, pp. 345-356. https://doi.org/10.1634/theoncologist.10-5-345
Pérez-Soler, Román ; Delord, Jean Pierre ; Halpern, Allan ; Kelly, Karen ; Krueger, James ; Sureda, Bartomeu Massuti ; Von Pawel, Joachim ; Temel, Jennifer ; Siena, Salvatore ; Soulières, Denis ; Saltz, Leonard ; Leyden, James. / HER1/EGFR inhibitor-associated rash : Future directions for management and investigation outcomes from the HER1/EGFR inhibitor rash management forum. In: Oncologist. 2005 ; Vol. 10, No. 5. pp. 345-356.
@article{e5c827f4436c49fdb252d6bec23f0bd5,
title = "HER1/EGFR inhibitor-associated rash: Future directions for management and investigation outcomes from the HER1/EGFR inhibitor rash management forum",
abstract = "Skin rash associated with HER1/epidermal growth factor receptor (EGFR) inhibitors is common. The lack of clinical and patient guidance for this often chronic and sometimes distressing side effect makes rash management and etiology investigation high priorities. To address this, oncologists and dermatologists with experience with HER1/EGFR inhibitors attended the HER1/EGFR Inhibitor Rash Management Forum. Recommendations include continued analysis of the correlation between rash and clinical outcome and improving the accuracy and reproducibility of terminology and grading systems. Because acne vulgaris has a unique pathology, and the pathology and etiology of rash are unclear yet distinct from acne vulgaris, using such terms as acne, acne-like, or acneiform should be avoided. Until there is a specific dermatological definition, rash is best described using phenotypic terms for its appearance and location. It is currently unknown which agents are best for treating rash. Clinical trials of rash treatments are urgently required, and suggestions for agents to consider are made based on current knowledge. The effect of dose reduction or interruption on rash should also be investigated. Secondarily infected rash may be more frequent than has been previously recognized, and some investigators favor empiric use of an oral antibiotic if this appears to be the case. Suggestions for patients include makeup to camouflage the rash and an emollient to prevent and alleviate skin dryness. The increasing use of HER1/EGFR-targeted agents makes managing rash important. We hope the outcomes from this Forum provide background for future studies.",
keywords = "Adverse event, HER1/EGFR, Monoclonal antibody, NSCLC, Rash, Survival, Tyrosine kinase inhibitor",
author = "Rom{\'a}n P{\'e}rez-Soler and Delord, {Jean Pierre} and Allan Halpern and Karen Kelly and James Krueger and Sureda, {Bartomeu Massuti} and {Von Pawel}, Joachim and Jennifer Temel and Salvatore Siena and Denis Souli{\`e}res and Leonard Saltz and James Leyden",
year = "2005",
month = "5",
doi = "10.1634/theoncologist.10-5-345",
language = "English (US)",
volume = "10",
pages = "345--356",
journal = "Oncologist",
issn = "1083-7159",
publisher = "AlphaMed Press",
number = "5",

}

TY - JOUR

T1 - HER1/EGFR inhibitor-associated rash

T2 - Future directions for management and investigation outcomes from the HER1/EGFR inhibitor rash management forum

AU - Pérez-Soler, Román

AU - Delord, Jean Pierre

AU - Halpern, Allan

AU - Kelly, Karen

AU - Krueger, James

AU - Sureda, Bartomeu Massuti

AU - Von Pawel, Joachim

AU - Temel, Jennifer

AU - Siena, Salvatore

AU - Soulières, Denis

AU - Saltz, Leonard

AU - Leyden, James

PY - 2005/5

Y1 - 2005/5

N2 - Skin rash associated with HER1/epidermal growth factor receptor (EGFR) inhibitors is common. The lack of clinical and patient guidance for this often chronic and sometimes distressing side effect makes rash management and etiology investigation high priorities. To address this, oncologists and dermatologists with experience with HER1/EGFR inhibitors attended the HER1/EGFR Inhibitor Rash Management Forum. Recommendations include continued analysis of the correlation between rash and clinical outcome and improving the accuracy and reproducibility of terminology and grading systems. Because acne vulgaris has a unique pathology, and the pathology and etiology of rash are unclear yet distinct from acne vulgaris, using such terms as acne, acne-like, or acneiform should be avoided. Until there is a specific dermatological definition, rash is best described using phenotypic terms for its appearance and location. It is currently unknown which agents are best for treating rash. Clinical trials of rash treatments are urgently required, and suggestions for agents to consider are made based on current knowledge. The effect of dose reduction or interruption on rash should also be investigated. Secondarily infected rash may be more frequent than has been previously recognized, and some investigators favor empiric use of an oral antibiotic if this appears to be the case. Suggestions for patients include makeup to camouflage the rash and an emollient to prevent and alleviate skin dryness. The increasing use of HER1/EGFR-targeted agents makes managing rash important. We hope the outcomes from this Forum provide background for future studies.

AB - Skin rash associated with HER1/epidermal growth factor receptor (EGFR) inhibitors is common. The lack of clinical and patient guidance for this often chronic and sometimes distressing side effect makes rash management and etiology investigation high priorities. To address this, oncologists and dermatologists with experience with HER1/EGFR inhibitors attended the HER1/EGFR Inhibitor Rash Management Forum. Recommendations include continued analysis of the correlation between rash and clinical outcome and improving the accuracy and reproducibility of terminology and grading systems. Because acne vulgaris has a unique pathology, and the pathology and etiology of rash are unclear yet distinct from acne vulgaris, using such terms as acne, acne-like, or acneiform should be avoided. Until there is a specific dermatological definition, rash is best described using phenotypic terms for its appearance and location. It is currently unknown which agents are best for treating rash. Clinical trials of rash treatments are urgently required, and suggestions for agents to consider are made based on current knowledge. The effect of dose reduction or interruption on rash should also be investigated. Secondarily infected rash may be more frequent than has been previously recognized, and some investigators favor empiric use of an oral antibiotic if this appears to be the case. Suggestions for patients include makeup to camouflage the rash and an emollient to prevent and alleviate skin dryness. The increasing use of HER1/EGFR-targeted agents makes managing rash important. We hope the outcomes from this Forum provide background for future studies.

KW - Adverse event

KW - HER1/EGFR

KW - Monoclonal antibody

KW - NSCLC

KW - Rash

KW - Survival

KW - Tyrosine kinase inhibitor

UR - http://www.scopus.com/inward/record.url?scp=20844448897&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=20844448897&partnerID=8YFLogxK

U2 - 10.1634/theoncologist.10-5-345

DO - 10.1634/theoncologist.10-5-345

M3 - Article

VL - 10

SP - 345

EP - 356

JO - Oncologist

JF - Oncologist

SN - 1083-7159

IS - 5

ER -